This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Varian Medical (VAR) Misses on Q1 Earnings and Revenues
by Zacks Equity Research
Varian Medical Systems, Inc. (VAR) reported adjusted earnings of 75 cents per share in the first quarter of fiscal 2017.
McKesson (MCK) Beats on Earnings in Q3, Inks Buyout Deal
by Zacks Equity Research
McKesson Corporation (MCK) reported third-quarter fiscal 2017 earnings of $3.03 per share, beating the Zacks Consensus Estimate of $2.95 but declining from the year-ago figure of $3.18.
Stryker (SYK) Beats Q4 Earnings, Provides FY17 Guidance
by Zacks Equity Research
Maintaining its streak of positive earnings surprises, Stryker Corp (SYK) reported adjusted earnings of $1.78 per share in the fourth quarter of 2016, which comfortably beat the Zacks Consensus Estimate by 2 cents.
Cynosure (CYNO) Looks Good: Stock Adds 6.6% in Session
by Zacks Equity Research
Cynosure, Inc. (CYNO) shares rose over 6% in the last trading session.
Can Glaukos (GKOS) Stock Continue to Grow Earnings?
by Zacks Equity Research
Glaukos (GKOS) has a favorable Zacks Rank and is a fast-growing stock that is well positioned for future earnings growth.
Zacks.com featured highlights: Glaukos, Apogee Enterprises, Braskem SA, Sundance Energy Australia and Angang Steel
by Zacks Equity Research
Zacks.com featured highlights: Glaukos, Apogee Enterprises, Braskem SA, Sundance Energy Australia and Angang Steel
Becton, Dickinson Commercially Launches Precise WTA Kits
by Zacks Equity Research
Becton, Dickinson and Company (BDX), popularly known as BD, recently announced that it has made its Precise whole transcriptome analysis kits commercial available.
Baxter (BAX): Sluggish Macro Environment Mars Prospects
by Zacks Equity Research
On Jan 17, we issued an updated research report on Deerfield, IL-based Baxter International Inc. (BAX), a global medical technology company and leading provider of renal and hospital products.
Zacks.com featured highlights: Glaukos, Daqo New Energy, Calavo Growers and Sucampo Pharmaceuticals
by Zacks Equity Research
Zacks.com featured highlights: Glaukos, Daqo New Energy, Calavo Growers and Sucampo Pharmaceuticals
Medidata Solutions Clinical Cloud Gets Picked by Celgene
by Zacks Equity Research
Medidata Solutions Inc. (MDSO) recently announced that Celgene Corporation adopted Medidata Clinical Cloud.
Pacific Biosciences (PACB) to Sell 10 PacBio Sequel Systems
by Zacks Equity Research
Pacific Biosciences of California, Inc. (PACB), announced that it will sell 10 PacBio Sequel Systems to Novogene Bioinformatics Technology Company, Ltd.
5 Stocks with Recent Price Strength to Boost Your Returns
by Zacks Equity Research
One should primarily target stocks that have recently been on a bullish run. Actually, stocks seeing price strength recently have a high chance of carrying the momentum forward.
Akers Biosciences (AKER) Closes Offering of 1.7M Shares
by Zacks Equity Research
Akers Biosciences, Inc. (AKER) recently announced the closing of a public offering of 1.7 million common shares.
4 Profitable Stocks with Amazingly High Returns
by Zacks Equity Research
Net income ratio gives us the exact profitability level of a company and reflects the percentage of net income to total sales revenue.
Intuitive Surgical (ISRG) Expects Strong Revenues in Q4
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) announced that it expects fourth-quarter 2016 revenues of approximately $757 million.
Fluidigm: Q4 Preliminary Results Fail to Cheer Investors
by Zacks Equity Research
The market is not really happy with South San Francisco, CA-based Fluidigm Corporation's (FLDM) preliminary results for the fourth quarter and full-year 2016.
Ecolab (ECL) Acquires Abednego Environmental, Shares Gain
by Zacks Equity Research
In a bid to strengthen its water solution line of offerings, St. Paul, MN-based Ecolab Inc. (ECL) announced the acquisition of Abednego Environmental Services.
Can the Rally in Glaukos (GKOS) Shares Continue?
by Zacks Equity Research
Glaukos Corporation (GKOS) has been on the move lately as the stock has risen by 12.1% in the past four weeks, and it is currently trading well above its 20-Day SMA.
DexCom Looking Forward to Strong Revenues in Q4 and 2016
by Zacks Equity Research
DexCom, Inc. (DXCM), a renowned medical device company, reported that it expects preliminary, unaudited revenue of approximately $168 million for the fourth quarter ended Dec 31, 2016.
Integra LifeSciences at 52-Week High on Deals, View Update
by Zacks Equity Research
Shares of Integra LifeSciences Holdings Corporation (IART), a global leader in medical technology, scaled a new 52-week high of $45.50 on Jan 10, closing a tad lower at $44.90.
Teleflex Launches LMA Gastro Airway, FDA Okays Arrow VPS
by Zacks Equity Research
Teleflex Inc. (TFX) recently announced the launch of LMA Gastro Airway with Cuff Pilot Technology and the receipt of 510(k) approval from the U.S. FDA for its Arrow VPS Rhythm device.
Glaukos (GKOS) Catches Eye: Stock Adds 5.6% in Session
by Zacks Equity Research
Glaukos Corporation (GKOS) moved big last session, as its shares jumped almost 6% on the day.
4 Med Instrument Stocks for Q3 Earnings amid Election Chaos
by Zacks Equity Research
The medical device sector is positioned for impressive growth in the near term.
5 Great Growth Stocks To Buy Now
by Brian Bolan
Revenue growth is the single biggest factor in selecting an aggressive growth stock.